NCT04736745View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.

PHASE1TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Moderate Upper Facial LinesSevere Upper Facial Lines
Interventions
BIOLOGICAL

IPN59011

Powder and solvent for solution for injection

BIOLOGICAL

Azzalure

Powder for solution for injection

DRUG

Placebo

Powder for solution for injection

Trial Locations (1)

D-13353

Clinical Research Centre (CRS), Berlin

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY